JHJoseph A. Hedrick

Joseph A. Hedrick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph A. Hedrick has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advancing the Integration of Digital Health Technologies in the Drug Development Ecosystem

    by Sakshi Sardar, Cheryl D Coon, Scottie Kern, Huong Huynh, Diane Stephenson, Joshua Rubin Abrams, Grace V Lee, Cecile Ollivier, Joseph A Hedrick, Martijn Ltm Müller, et al.

    Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.


  • Open Access

    Advancing the Integration of Digital Health Technologies in the Drug Development Ecosystem (Preprint)

    by Sakshi Sardar, Cheryl D Coon, Scottie Kern, Huong Huynh, Diane Stephenson, Joshua Rubin Abrams, Grace V Lee, Cecile Ollivier, Joseph A Hedrick, Martijn Ltm Müller, et al.

    UNSTRUCTURED Optimized frameworks for efficient and scalable deployment of digital health technologies (DHT) are needed to address existing bottlenecks and unlock the opportunities for remote monitoring and operationalizing decentralized trials. DHTs offer immense potential opportunities for transformation in drug development by providing remote, high frequency, longitudinal insights into physiological processes, and how participants feel and function. Currently, DHT-based drug development tool–related efforts have yielded valuable insights into effective practices and areas that need improvement. However, the development of the required infrastructure is a resource-intensive task, and its efficiency can be greatly enhanced by systematically identifying the required components and aligning them in ways that will avoid trial-and-error approaches by various stakeholders. In this perspective paper, we aim to highlight these crucial aspects required for supporting the rapid and large-scale deployment of DHTs. We propose the development of various standardized consensus frameworks to clearly lay out processes for various stakeholders and facilitate the seamless integration of the next generation of health care–sensing technologies into drug development.

  • The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes

    by Ambroise Gilles, Lan Hu, Francesca Virdis, Derek B. Sant’angelo, Nevenka Dimitrova, Joseph A Hedrick, Lisa K. Denzin

    Peptide loading of MHC class II (MHCII) molecules is facilitated by HLA-DM (DM), which catalyzes CLIP release, stabilizes empty MHCII, and edits the MHCII-bound peptide repertoire. HLA-DO (DO) binds to DM and modulates its activity, resulting in an altered set of peptides presented at the cell surface. MHCII–peptide presentation in individuals with type 1 diabetes (T1D) is abnormal, leading to a breakdown in tolerance; however, no direct measurement of the MHCII pathway activity in T1D patients has been performed. In this study, we measured MHCII Ag-processing pathway activity in humans by determining MHCII, MHCII–CLIP, DM, and DO levels by flow cytometry for peripheral blood B cells, dendritic cells, and monocytes from 99 T1D patients and 97 controls. Results showed that MHCII levels were similar for all three APC subsets. In contrast, MHCII–CLIP levels, independent of sex, age at blood draw, disease duration, and diagnosis age, were significantly increased for all three APCs, with B cells showing the largest increase (3.4-fold). DM and DO levels, which usually directly correlate with MHCII–CLIP levels, were unexpectedly identical in T1D patients and controls. Gene expression profiling on PBMC RNA showed that DMB mRNA was significantly elevated in T1D patients with residual C-peptide. This resulted in higher levels of DM protein in B cells and dendritic cells. DO levels were also increased, suggesting that the MHCII pathway maybe differentially regulated in individuals with residual C-peptide. Collectively, these studies show a dysregulation of the MHCII Ag-processing pathway in patients with T1D.


  • Open Access

    Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders

    by Mark R. Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A. Hedrick, Teresa Quattrin

    OBJECTIVE: The T1GER (A Study of SIMPONI to Arrest β-Cell Loss in Type 1 Diabetes) study showed many metabolic benefits of the tumor necrosis factor-α blocker golimumab in children and young adults with type 1 diabetes (T1D). Off-therapy effects are reported.RESEARCH DESIGNS AND METHODS: T1GER was a phase 2, placebo-controlled, randomized trial in which golimumab or placebo was administered for 52 weeks to participants 6–21 years old diagnosed with T1D within 100 days of randomization. Assessments occurred during the 52-week on-therapy and 52-week off-therapy periods.RESULTS: After treatment was stopped, C-peptide area under the curve (AUC) remained greater in the treatment versus control group. At weeks 78 and 104, the golimumab group had lower reductions in the 4-h C-peptide AUC baseline than the placebo group, where specifically the golimumab group had reductions of 0.31 and 0.41 nmol/L, and the placebo group had reductions of 0.64 and 0.74 nmol/L. There were also trends in less insulin use, higher peak C-peptide levels and those in partial remission, and higher peak C-peptide levels in the golimumab group. Golimumab responders, defined as having an increase or minimal loss of C-peptide AUC and/or being in partial remission at week 52, showed even greater improvements in most metabolic parameters on and off therapy and had less hypoglycemia during the off-therapy period versus placebo. Adverse events, including infections, were similar between the groups during all time periods of the study.CONCLUSIONS: In children and young adults with new-onset T1D, golimumab preserved endogenous β-cell function and resulted in other favorable metabolic parameters on and off therapy. A subpopulation had disease stabilization while on therapy, with improved metabolic parameters off therapy.


  • Open Access

    A reference database for tumor-related genes co-expressed with interleukin-8 using genome-scale in silico analysis

    by Lawrence Benbow, Lynn Wang, Maureen Laverty, Suxing Liu, Ping Qiu, Richard W Bond, Eric Gustafson, Joseph A Hedrick, Mitchell Kostich, Jonathan R Greene, et al.

    The EST database provides a rich resource for gene discovery and in silico expression analysis. We report a novel computational approach to identify co-expressed genes using EST database, and its application to IL-8. IL-8 is represented in 53 dbEST cDNA libraries. We calculated the frequency of occurrence of all the genes represented in these cDNA libraries, and ranked the candidates based on a Z-score. Additional analysis suggests that most IL-8 related genes are differentially expressed between non-tumor and tumor tissues. To focus on IL-8's function in tumor tissues, we further analyzed and ranked the genes in 16 IL-8 related tumor libraries. This method generated a reference database for genes co-expressed with IL-8 and could facilitate further characterization of functional association among genes.